Since the publication of the first issue of Nature Reviews Clinical Oncology, we have
witnessed advances in multiple research areas that have culminated in improved outcomes …

The treatment of prostate cancer (PCa) has made great progress in recent years, but
treatment resistance always develops and can even lead to fatal disease. Exploring the …

Abstract Background/Aim: We aimed to evaluate the changes of androgen receptor (AR)
signaling-related long non-coding RNAs (lncRNAs) in serum extracellular vesicles (EVs) …

The advent of high-throughput technologies has enabled the analysis of minute amounts of
tumor-derived material purified from body fluids, termed “liquid biopsies.” Prostate cancer …

Prostate cancer is the second most prevalent cancer in men globally. De novo
neuroendocrine prostate cancer (NEPC) is uncommon at initial diagnosis …

Background: Management strategies for metastatic castration-resistant prostate cancer
(mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic …

Background Metastatic prostate cancer is a highly heterogeneous and dynamic disease and
practicable tools for patient stratification and resistance monitoring are urgently needed …

Neuroendocrine prostate cancer is complex, comprising a wide spectrum of phenotypes,
which has led to very different entities being inappropriately lumped together or assumed to …

Despite the clinical advances in managing metastatic prostate cancer in the last 20 years,
treatments for patients with metastatic disease only offer a brief respite from disease …

Neuroendocrine prostate cancer (NEPC) is an aggressive advanced subtype of prostate
cancer that exhibits poor prognosis and broad resistance to therapies. Currently, few …